Scotch Plains, NJ, United States of America

Dmitri A Pissarnitski

USPTO Granted Patents = 25 (Patent Applications = 9)

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 12 (Patent Applications = 21)

Average Co-Inventor Count = 7.5

ph-index = 6

Forward Citations = 230(Granted Patents)

Company Filing History:

15 out of 2,405

Merck Sharp + Dohme Corp.

Pharacopeia Drug Discovery, Inc.

patent

4. 3 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 2004-2025

Loading Chart...

25 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12427187 - Glucose-responsive insulin conjugates (2025-09-30),

2. 11820805 - Conjugate based systems for controlled insulin delivery (2023-11-21),

3. 11041009 - Glucose responsive insulin comprising a tri-valent sugar cluster for treatment of diabetes (2021-06-22),

4. 10800827 - Insulin receptor partial agonists (2020-10-13),

5. 10689430 - Insulin receptor partial agonists (2020-06-23),

6. 10183981 - Insulin receptor partial agonists (2019-01-22),

7. 10017556 - Insulin receptor partial agonists (2018-07-10),

8. 9464103 - Spirocyclic sulfones as gamma secretase inhibitors (2016-10-11),

9. 9156872 - 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases (2015-10-13),

10. 9150603 - 2'-cyano substituted nucleoside derivatives and methods of use thereof useful for the treatment of viral diseases (2015-10-06),

11. 9096582 - Gamma secretase modulators (2015-08-04),

12. 9061041 - 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases (2015-06-23),

13. 8759337 - Gamma secretase modulators (2014-06-24),

14. 8691832 - Tricyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors (2014-04-08),

15. 8664411 - Tetrahydropyranochromene gamma secretase inhibitors (2014-03-04),

Title: The Innovative Work of Dmitri A Pissarnitski in Controlled Insulin Delivery

Introduction: Dmitri A Pissarnitski, a prolific inventor based in Scotch Plains, NJ, has made significant contributions to the field of controlled insulin delivery through his groundbreaking research and patented inventions. With a total of 24 patents to his name, Pissarnitski is known for his expertise in developing advanced systems for managing diabetes with greater precision and effectiveness.

Latest Patents: Among his latest patents, one notable invention is the "Conjugate based systems for controlled insulin delivery." This patent discloses novel conjugates that combine insulin molecules with saccharide ligands and fatty chains to enhance the pharmacokinetic and pharmacodynamic properties of insulin when administered to mammals. Additionally, Pissarnitski's "Glucose responsive insulin comprising a tri-valent sugar cluster for treatment of diabetes" patent introduces an insulin conjugate designed to respond to systemic saccharide concentrations, offering a more tailored approach to diabetes treatment.

Career Highlights: Pissarnitski has amassed a wealth of experience working with renowned companies in the pharmaceutical industry. He has held positions at Merck Sharp & Dohme Corporation and Schering Corporation, where he has honed his skills in drug development and biomedical research. His expertise in insulin delivery systems has led to the successful implementation of innovative solutions for managing diabetes.

Collaborations: Throughout his career, Pissarnitski has collaborated with esteemed colleagues such as Hubert B Josien and John W Clader. These partnerships have been instrumental in advancing the field of controlled insulin delivery and developing cutting-edge technologies that improve the quality of life for patients with diabetes.

Conclusion: Dmitri A Pissarnitski's pioneering work in controlled insulin delivery stands as a testament to his dedication to innovation and scientific excellence. His patented inventions not only showcase his talent as an inventor but also highlight his commitment to revolutionizing the treatment of diabetes. Pissarnitski's contributions continue to have a lasting impact on the healthcare industry, offering new possibilities for more effective and personalized therapies for individuals living with diabetes.

This text is generated by artificial intelligence and may not be accurate.